New data suggest
that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the
onset of a new episode of depression in patients who had previously
responded to the medication and who had recurrent depressive
disorder, defined in the study as those patients who experienced at
least three depressive episodes in the previous five years, compared
with placebo (p […]

Addrenex Pharmaceuticals
announced that the U.S. Food and Drug Administration has approved its
Investigational New Drug Application (IND) for ADX415, a novel hypertension
drug. With the approval, Addrenex has launched a phase 2 clinical trial to
study ADX415 as a targeted therapy for hypertension.
The phase 2 trial is a multicenter,

Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced the final analysis of its European Phase III double-blind placebo-controlled study of PSD502 for the